Stock Report

All about this stock under one free report Last Updated: 20-Oct-2026

Stock Rating

See the stock’s health at a glance, before it's too late.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Ind-Swift Lab Peer Comparison

Stock Card factsheet watchlist-stock-modal share-fund-plan-icon

NSE: INDSWFTLAB | BSE: 532305

₹351.90

up-down-arrow ₹-7.35 (-2.05%)

As on 19-Oct-2026IST

Market cap

info icon

₹3,114 Cr

Revenue (TTM)

info icon

₹665 Cr

P/E Ratio

info icon

54.3

P/B Ratio

info icon

2.2

Div. Yield

info icon

0 %

Edit peer-selector-edit
Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Market cap (₹ Cr)
 3,114 33,487 24,665 15,628 13,421
Revenue (₹ Cr)
 665 9,683 2,372 2,590 1,108
Net Profit (₹ Cr)
 57.24 1,018.97 497.77 603.02 270.18
Net Margin (%)
 7.95 10.47 20.72 22.63 23.29
RoE (%)
 5.01 21.30 28.49 19.61 14.45
Price to Earnings
 54.32 33.11 49.55 25.92 48.74
Price-To-Book
 2.17 6.40 12.20 4.48 6.47

Income Statement (₹ Cr)

Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Operating Revenue arrow
664.74 9,683.45 2,371.81 2,590.40 1,108.39
Total Income arrow
720.05 9,730.84 2,402.61 2,664.23 1,159.90
Total Expenditure arrow
605.08 7,739.53 1,608.91 1,753.71 720.01
EBITDA arrow
59.65 1,943.92 762.90 836.69 388.38
Depreciation arrow
31.51 425.10 98.11 78.88 74.78
EBIT arrow
28.14 1,518.82 664.79 757.81 313.60
Interest arrow
0.96 148.45 26.33 5.43 0.26
Other Income arrow
55.31 47.39 30.80 73.83 51.50
Exceptional Items arrow
-11.24 -27.85 0.00 -25.66 -3.28
Profit before Tax arrow
71.25 1,389.91 669.26 800.55 361.56
Provision for Tax arrow
14.01 370.94 171.48 197.53 91.39
Profit after Tax arrow
57.24 1,018.97 497.77 603.02 270.18

Liabilities (₹ Cr)

Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Shareholder's Funds arrow
1,384.02 4,950.03 1,874.47 3,332.13 2,017.06
Minority Interest arrow
0.00 -7.58 0.00 0.00 2.51
Non-Current Liabilities arrow
32.10 723.57 345.47 142.73 50.51
Current Liabilities arrow
257.29 3,912.24 710.20 508.04 169.08
Total Liabilities arrow
1,673.35 9,514.48 2,930.14 4,157.10 2,231.79

Assets (₹ Cr)

Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Non-Current Assets arrow
674.52 3,392.16 1,290.62 1,321.38 957.22
Current Assets arrow
976.75 5,612.10 1,483.13 2,649.36 1,250.11
Total Assets arrow
1,673.35 9,514.48 2,930.14 4,157.10 2,231.79
Total Debt* arrow
17.70 1,204.08 196.61 0.00 0.00
Net Current Assets arrow
719.47 1,699.86 772.93 2,141.33 1,081.04
Contingent Liabilities arrow
66.38 258.92 13.18 4.82 3.76

Cashflow (₹ Cr)

Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Cash From Operating Activities arrow
-68.17 943.55 346.68 565.41 266.88
Cash Flow from Investing Activities arrow
-72.68 -1,193.06 -423.73 -570.15 -142.72
Cash from Financing Activities arrow
141.81 343.43 20.98 -64.34 -112.88
Net Cash Inflow / Outflow arrow
0.96 93.92 -56.08 -69.08 11.28

Ratios

Profitability Ratios

 Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
ROCE (%) arrow
4.00 25.25 27.50 24.61 18.04
ROE (%) arrow
5.01 21.30 28.49 19.61 14.45
ROA (%) arrow
3.68 11.42 19.48 16.31 12.66
EBIT Margin (%) arrow
4.23 15.68 28.03 29.25 28.29
Net Margin (%) arrow
7.95 10.47 20.72 22.63 23.29
Cash Profit Margin (%) arrow
0.00 0.00 0.00 0.00 0.00

Growth Ratios

 Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Revenue Growth (%) arrow
15.05 18.36 78.33 7.93 -6.72
EBIT Growth (%) arrow
214.93 30.43 303.07 19.88 -26.64
Net Profit Growth (%) arrow
-75.11 32.39 182.61 21.66 -24.38
EPS Growth (%) arrow
114.38 36.68 277.72 25.42 -21.99
Book Value Growth (%) arrow
25.86 11.36 22.95 18.43 11.27

Valuation Ratios

 Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Price / Earnings arrow
44.53 32.43 49.55 25.09 48.31
Price / Book Value arrow
2.17 6.40 12.20 4.48 6.47
Dividend Yield (%) arrow
0.00 0.20 0.18 0.39 0.59
EV/EBITDA arrow
45.09 17.77 32.12 17.74 33.49
Market Cap (₹ Cr) arrow
1,142.74 30,257.56 15,412.11 11,956.86 10,627.92

Solvency Ratios

 Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debt to Equity arrow
0.01 0.05 0.09 0.00 0.00
Short term debt to equity ratio arrow
0.00 0.16 -- -- --
Current Ratio arrow
3.80 1.43 2.09 5.21 7.39
Quick Ratio arrow
3.22 0.82 1.37 3.85 5.46
Interest Coverage arrow
75.30 10.36 26.41 148.49 1,386.30

Operating Efficiency Ratios

 Ind-Swift Lab Emcure Pharmaceuticals Neuland Lab Alivus Life Sciences Concord Biotech
Debtors to sales (%) arrow
29.87 26.46 22.82 41.42 41.52
Asset Turnover arrow
0.43 1.09 0.93 0.70 0.52
Receivable days arrow
97.45 88.68 77.32 144.58 169.86
Inventory Days arrow
70.35 84.11 80.83 96.67 97.92
Payable days arrow
162.26 176.65 125.94 135.45 159.68
Cash Conversion Cycle arrow
5.54 -3.86 32.22 105.80 108.11
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...